News

ADOCIA Reports Second Quarter 2025 Financial Results and Provides a Business Update
Cash position of €7.1 million as of June 30, 2025 US$10 million milestone payment from partner Tonghua Dongbao and 2024 Research Tax Credit of €2.8 million received in July 2025 Current ...
Zacks Investment Research on MSN2d
Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?
Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest ...
Novo Nordisk: The Market Hasn't Given It Enough Respect
Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for ...
Novo Nordisk's Moat Is Deeper Than You Think
Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...
2 Beaten-Down Dividend Growth Stocks to Buy on the Dip
It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high. Shares of Novo Nordisk and ...
24/7 Wall St.4d
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (July 2025)
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
A Once-in-a-Lifetime Opportunity: This Blue Chip Healthcare Stock Down 50% Could Double Your Money
Key Points Novo Nordisk's recent financial results and clinical progress haven't impressed Wall Street.However, the company ...